126 related articles for article (PubMed ID: 27306821)
1. [A Case of Drug-Induced Lung Injury Associated with Paclitaxel plus Bevacizumab Therapy].
Yamaguchi Y; Tada Y; Takaya S; Iwamoto A; Yamashiro Y; Shibata S; Ishiguro M; Nishidoi H
Gan To Kagaku Ryoho; 2016 Jun; 43(6):781-4. PubMed ID: 27306821
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced breast cancer with bleeding - two cases effectively treated with bevacizumab plus weekly paclitaxel.
Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
Gan To Kagaku Ryoho; 2014 May; 41(5):637-40. PubMed ID: 24917012
[TBL] [Abstract][Full Text] [Related]
3. [A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].
Komaki C; Hanatate F; Kobayashi K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):113-6. PubMed ID: 21368470
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Yoshinami T; Yagi T; Okuno J; Kittaka N; Ishitobi M; Sugimoto N; Nakayama T; Tamaki Y; Imamura F
Breast Cancer; 2017 Jan; 24(1):147-151. PubMed ID: 27010394
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
6. [Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Sakamoto M; Nio Y; Imai S; Uesugi K; Tamaoki M; Tamaoki M
Gan To Kagaku Ryoho; 2017 Jul; 44(7):579-584. PubMed ID: 28790261
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
[TBL] [Abstract][Full Text] [Related]
8. [Liver Atrophy and Failure Associated with Paclitaxel and Bevacizumab Combination Therapy for Metastatic Breast Cancer].
Yamamoto M; Ikeda M; Kubo S; Tsukioki T; Nakamoto S
Gan To Kagaku Ryoho; 2016 Jul; 43(7):869-73. PubMed ID: 27431631
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of bevacizumab with paclitaxel for advanced breast cancer - a case report].
Morishita A; Mitsuhashi S; Fujisawa F; Hirano M; Kojima H
Gan To Kagaku Ryoho; 2013 Jun; 40(6):761-4. PubMed ID: 23863653
[TBL] [Abstract][Full Text] [Related]
10. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
[TBL] [Abstract][Full Text] [Related]
11. [Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel].
Terada M; Sugiura H; Yoshimoto N; Nishikawa S; Ito Y; Kawaguchi Y; Ando Y; Hato Y
Gan To Kagaku Ryoho; 2017 Jul; 44(7):591-593. PubMed ID: 28790263
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - A Case Report].
Nakayama I
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1391-1392. PubMed ID: 29394644
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Disseminated Bone Marrow Carcinomatosis Arising from Breast Cancer for Which Paclitaxel and Bevacizumab Treatment Was Effective].
Kamata A; Hagiwara H; Koizumi M; Sarukawa H; Wada Y; Miyamae T; Abe Y; Takahashi K; Kano T; Natori J; Uchiyama K
Gan To Kagaku Ryoho; 2016 Jan; 43(1):103-6. PubMed ID: 26809535
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
16. [Breast Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine Monotherapy after Failure of Combination Therapy Comprising Bevacizumab and Paclitaxel].
Ooe A; Suganuma Y
Gan To Kagaku Ryoho; 2016 Mar; 43(3):349-51. PubMed ID: 27067853
[TBL] [Abstract][Full Text] [Related]
17. [A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Biweekly Paclitaxel and Bevacizumab].
Yoshida T; Goto Y; Sakiyama K; Kimura M
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1397-1400. PubMed ID: 27899783
[TBL] [Abstract][Full Text] [Related]
18. Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Armstrong P; Woody MM; Reichenberg JS; Gavino AC
Cutis; 2018 Sep; 102(3):E12-E14. PubMed ID: 30372726
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
Watanabe N; Furukawa J; Minoji T; Tamai K; Kitahara T; Yamamura N; Okamura S; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1097-1099. PubMed ID: 30042280
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
